NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Forecast, Price & News $66.85 -3.04 (-4.35%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$66.64▼$70.0050-Day Range$66.85▼$82.2152-Week Range$38.87▼$91.29Volume1.04 million shsAverage Volume633,929 shsMarket Capitalization$3.15 billionP/E RatioN/ADividend YieldN/APrice Target$104.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside56.3% Upside$104.45 Price TargetShort InterestBearish17.21% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.35Based on 6 Articles This WeekInsider TradingSelling Shares$828,293 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.04) to ($2.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.70 out of 5 starsMedical Sector79th out of 975 stocksPharmaceutical Preparations Industry19th out of 454 stocks 4.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $104.45, Axsome Therapeutics has a forecasted upside of 56.3% from its current price of $66.85.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.21% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 1.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 1.9 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Axsome Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 15 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $828,293.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.60% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.04) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 26.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics (NASDAQ:AXSM) StockAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesOctober 3, 2023 | markets.businessinsider.comMaintaining Buy Rating for Axsome Therapeutics: Steady Auvelity Sales and Anticipated Q3 Performance InsightsOctober 2, 2023 | finance.yahoo.comAxsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness WeekOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."October 1, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7%September 28, 2023 | businesswire.comAXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 28, 2023 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 26, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from MizuhoSeptember 21, 2023 | finance.yahoo.comAxsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy DayOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 19, 2023 | finance.yahoo.comAxsome Therapeutics, Inc.'s (NASDAQ:AXSM) Earnings Haven't Escaped The Attention Of InvestorsSeptember 10, 2023 | realmoney.thestreet.comThis Promising Biotech Is Just Right for a Covered-Call PlaySeptember 7, 2023 | finance.yahoo.comAxsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023September 5, 2023 | finance.yahoo.comAxsome Therapeutics to Present at Three Upcoming Investor ConferencesSeptember 1, 2023 | seekingalpha.comAxsome: Beyond The Numbers - Q2 Earnings Sparkle And A Pipeline Full Of PromiseAugust 22, 2023 | nasdaq.comCantor Fitzgerald Reiterates Axsome Therapeutics (AXSM) Overweight RecommendationAugust 16, 2023 | msn.comBofA upgrades Axsome to neutral, cites improved outlook for MDD drugAugust 12, 2023 | msn.comMizuho Maintains Axsome Therapeutics (AXSM) Buy RecommendationAugust 9, 2023 | finance.yahoo.comAxsome Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAugust 9, 2023 | msn.comPiper Sandler Upgrades Axsome Therapeutics (AXSM)August 9, 2023 | msn.comB of A Securities Upgrades Axsome Therapeutics (AXSM)August 8, 2023 | msn.comBofA upgrades Axome to neutral, cites improved outlook for MDD drugAugust 8, 2023 | finance.yahoo.comAxsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline UpdatesAugust 8, 2023 | finance.yahoo.comDraftKings upgraded, Home Depot downgraded: Wall Street's top analyst callsAugust 8, 2023 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Stoke Therapeutics (STOK) and Cassava Sciences (SAVA)August 8, 2023 | finance.yahoo.comQ2 2023 Axsome Therapeutics Inc Earnings CallAugust 7, 2023 | nasdaq.comAxsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue EstimatesSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Company Calendar Last Earnings8/07/2023Today10/03/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees422Year FoundedN/APrice Target and Rating Average Stock Price Forecast$104.45 High Stock Price Forecast$180.00 Low Stock Price Forecast$81.00 Forecasted Upside/Downside+56.3%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,130,000.00 Net Margins-101.07% Pretax Margin-100.00% Return on Equity-92.39% Return on Assets-36.35% Debt Debt-to-Equity Ratio0.63 Current Ratio4.52 Quick Ratio4.44 Sales & Book Value Annual Sales$50.04 million Price / Sales63.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.52 per share Price / Book26.53Miscellaneous Outstanding Shares47,190,000Free Float35,629,000Market Cap$3.15 billion OptionableOptionable Beta1.91 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 55)Founder, Chairman, CEO & Pres Comp: $1.32MMr. Nick Pizzie CPA (Age 48)M.B.A., Chief Financial Officer Comp: $732.94kMr. Mark L. Jacobson (Age 40)COO & Sec. Comp: $784.66kMr. Hunter Murdock Esq. (Age 43)Gen. Counsel & Sec. Comp: $735.39kDr. Amanda Jones Pharm.D. (Age 40)Sr. VP of Clinical Devel. Ms. Lori Englebert M.B.A. (Age 45)Exec. VP of Commercial & Bus. Devel. Joseph Debrah-Afful CPAM.B.A., Director of Fin.More ExecutivesKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXEvotecNASDAQ:EVOCorcept TherapeuticsNASDAQ:CORTAmicus TherapeuticsNASDAQ:FOLDCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsMark ColemanSold 11,016 sharesTotal: $828,293.04 ($75.19/share)Perceptive Advisors LLCBought 271,493 shares on 8/24/2023Ownership: 0.575%Wolverine Trading LLCBought 700 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 1,042 shares on 8/21/2023Ownership: 0.088%Affinity Asset Advisors LLCBought 12,500 shares on 8/21/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions AXSM Stock - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price forecast for 2023? 11 Wall Street analysts have issued 1 year price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $81.00 to $180.00. On average, they anticipate the company's share price to reach $104.45 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2023? Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM shares have decreased by 13.3% and is now trading at $66.85. View the best growth stocks for 2023 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its earnings results on Monday, August, 7th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.24. The firm earned $46.70 million during the quarter, compared to analyst estimates of $40.19 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 92.39% and a negative net margin of 101.07%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $66.85. How much money does Axsome Therapeutics make? Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.15 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis. How many employees does Axsome Therapeutics have? The company employs 422 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245. This page (NASDAQ:AXSM) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.